Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled time : 13:15 save search
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
Published: 2021-11-09 (Crawled : 13:15) - biospace.com/
ALDX 4 | $3.98 2.84% 2.76% 640K
|
Health Technology
|
| O: 1.11%
H: 3.41%
C: 1.76%
new drug dry eye disease eye application eye disease drug phase 3 trial submission enroll
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
Published: 2021-11-05 (Crawled : 13:15) - biospace.com/
LGVN | News P 6 d | $2.08 -41.08% -69.71% 3.3M
|
|
| O: -3.05%
H: 0.61%
C: -5.57%
disease alzheimer phase 2 research trial alzheimer’s alzheimer's disease alzheimer's
Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease
Published: 2021-10-25 (Crawled : 13:15) - biospace.com/
ENDP | $0.2926 -9.6%
|
Health Technology
|
| O: 0.0%
H: 3.9%
C: 2.39%
disease
LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide™ Genome Editing Technology
Published: 2021-10-21 (Crawled : 13:15) - biospace.com/
LOGC | $2.07 -0.48%
|
Health Technology
|
| O: 5.2%
H: 0.0%
C: -8.24%
disease genome editing technology liver
Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease
Published: 2021-10-21 (Crawled : 13:15) - biospace.com/
SELB M | $0.8812 -8.0% 2.12% 0
|
Health Technology
|
| O: 0.0%
H: 4.37%
C: 1.54%
disease gene therapy therapy license
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
Published: 2021-10-19 (Crawled : 13:15) - nantkwest.com
IBRX | $5.25 6.71% 6.29% 4.3M
|
Manufacturing
|
| O: 0.9%
H: 2.89%
C: 1.78%
disease bladder cancer cancer trial bladder
Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program
Published: 2021-10-14 (Crawled : 13:15) - biospace.com/
RYTM A | $38.4 -0.31% -0.31% 600K
|
Health Technology
|
| O: 1.68%
H: 8.09%
C: 0.52%
disease obesity genetic test rare
Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
Published: 2021-10-12 (Crawled : 13:15) - biospace.com/
ATXS | $10.53 -5.14% -5.41% 550K
|
Manufacturing
|
| O: 0.0%
H: 5.68%
C: 4.47%
disease treatment rare hereditary angioedema
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Published: 2021-10-06 (Crawled : 13:15) - biospace.com/
SAVA | $21.27 1.14% 1.13% 630K
|
Health Technology
|
| O: -0.51%
H: 5.45%
C: -7.68%
disease alzheimer treatment phase 3 trial refocus-alz rethink-alz alzheimer’s alzheimer's disease alzheimer's
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Published: 2021-09-27 (Crawled : 13:15) - biospace.com/
ATRA | $0.7201 5.65% 5.35% 830K
|
Health Technology
|
| O: 1.0%
H: 3.09%
C: 1.75%
disease treatment europe positive iot tab-cel cel
AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
Published: 2021-09-20 (Crawled : 13:15) - prnewswire.com
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: -1.33%
H: 1.31%
C: 0.28%
disease treatment fda risankizumab order
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
Published: 2021-09-08 (Crawled : 13:15) - globenewswire.com
GANX | $3.14 -0.63% -0.64% 81K
|
Professional, Scientific, and T...
|
| O: 19.11%
H: 3.61%
C: 0.85%
disease treatment positive topline parkinson
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
Published: 2021-09-07 (Crawled : 13:15) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 1.23%
H: 1.51%
C: -2.39%
new drug disease treatment fda oxbryta children drug fda acceptance
AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
Published: 2021-05-24 (Crawled : 13:15) - prnewswire.com
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: 0.4%
H: 0.19%
C: -0.58%
disease risankizumab
INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
Published: 2021-05-24 (Crawled : 13:15) - globenewswire.com
INMB | $8.51 -7.0% -7.52% 150K
|
Health Technology
|
| O: 3.52%
H: 0.14%
C: -10.88%
disease alzheimer alzheimer’s alzheimer's disease alzheimer's
ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021
Published: 2021-05-20 (Crawled : 13:15) - nantkwest.com
IBRX | $5.25 6.71% 6.29% 4.3M
|
Manufacturing
|
| O: 0.19%
H: 9.44%
C: 6.5%
disease phase 2 lung cancer therapy cancer enroll
Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer’s Disease Panel
Published: 2021-05-20 (Crawled : 13:15) - ir.stockpr.com
CYTH | $1.25 2.46% 2.4% 31K
|
Professional, Scientific, and T...
|
| O: 0.56%
H: 5.76%
C: 5.2%
disease alzheimer conference alzheimer’s alzheimer's disease alzheimer's
Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
Published: 2021-05-14 (Crawled : 13:15) - globenewswire.com
CLRB | $3.2 -3.32% -3.44% 840K
|
Health Technology
|
| O: 4.8%
H: 2.29%
C: -1.53%
disease rare
CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical OfficerExperienced Biotech Executive, Physician-Scientist and Orphan Disease Expert to Lead Clinical/Medical Functions as Seladelpar Advances in Phase 3 and as Pipeline Programs Mature
Published: 2021-05-13 (Crawled : 13:15) - biospace.com/
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: -1.72%
H: 2.7%
C: -2.4%
disease biotech phase 3 iot
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
Published: 2021-05-13 (Crawled : 13:15) - globenewswire.com
LUMO | $2.52 3.16% 14K
|
Health Technology
|
| O: -0.1%
H: 3.96%
C: -2.4%
disease rare pharma
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.